Diagnostic Challenges and Evolving Care in Wilson Disease

Although Wilson disease is considered rare, experts at a recent HCPLive clinical forum convened by Valentina Medici, MD, a professor in the division of Gastroenterology and Hepatology at University of California Davis, emphasized that its true prevalence may be underestimated due to frequent underdiagnosis and delayed recognition.

A rare inherited multisystem disorder affecting approximately 1 in 30,000 individuals worldwide, Wilson disease primarily impacts hepatic and neurological function and stems from pathogenic mutations in the ATP7B gene, which impairs the liver’s ability to excrete excess copper. Copper accumulation damages the liver and brain, and without daily treatment, the disease is fatal.

At the forum, clinicians discussed real-world challenges in identifying and managing the disease, highlighting diagnostic uncertainty, variability in presentation, and evolving treatment approaches.

Participants noted that most clinicians encounter only a small number of cases throughout their careers, limiting familiarity and contributing to missed or delayed diagnoses. While the disease is traditionally considered uncommon, emerging data suggest that genetic prevalence may exceed clinical detection, reinforcing concerns that many cases go unrecognized.

A Rare Disease With Broad, Atypical Presentations

A central theme of the discussion was the heterogeneity of Wilson disease. While hepatic manifestations are the most common, it can affect multiple organ systems, including the brain, kidneys, and musculoskeletal system.

Of note, only about half of patients present with “classic” features. The remaining patients fall into less typical presentations, which may include subtle liver abnormalities, neurologic symptoms, or psychiatric changes.

Panelists emphasized that these atypical cases are a major driver of missed diagnoses. Patients are often initially labeled with more common conditions such as fatty liver disease or autoimmune hepatitis, particularly when liver enzyme abnormalities are mild or nonspecific.

Neurologic and psychiatric symptoms can further complicate recognition. Movement disorders, tremors, and speech abnormalities may emerge gradually, while psychiatric manifestations like anxiety or behavioral changes are often underrecognized and difficult to attribute to an underlying metabolic disorder.

Diagnostic “Gray Zones” and Testing Limitations

Despite established diagnostic criteria, experts highlighted persistent challenges with commonly used tests. Ceruloplasmin, a widely used screening tool, lacks sensitivity and specificity and may be normal or borderline in some patients.

Similarly, 24-hour urinary copper excretion and hepatic copper quantification can be influenced by factors such as inflammation, cholestasis, and treatment status, further complicating interpretation.

These limitations contribute to what panelists described as “diagnostic gray zones,” where clinical suspicion may be high but test results remain inconclusive. In these cases, clinicians often must integrate multiple data points, including clinical presentation, laboratory findings, and, when available, genetic testing.

The Leipzig scoring system was referenced as a helpful framework, though experts acknowledged that it does not fully resolve diagnostic ambiguity in complex cases.

Ultimately, panelists emphasized that clinical suspicion remains critical, particularly in younger patients with unexplained liver abnormalities or neurologic symptoms.

Delays in Diagnosis, Missed Opportunities

The forum highlighted significant delays in diagnosing Wilson disease, particularly in patients with neurologic or psychiatric presentations. In some cases, diagnosis may be delayed by several years, with psychiatric manifestations taking even longer to be correctly attributed to the disease.

These delays can have serious consequences, as untreated disease may progress to advanced liver disease, neurologic impairment, or acute liver failure. Clinicians shared examples of patients presenting late in the disease course, including those requiring urgent liver transplantation.

Panelists stressed that maintaining a high index of suspicion is essential, especially given the overlap between Wilson disease and more common conditions. Even borderline laboratory findings should prompt further evaluation when clinical concern remains high.

A Multidisciplinary Approach to Treatment

Management of Wilson disease extends beyond copper reduction alone. While chelation therapy and zinc remain the foundation of treatment, experts emphasized the need to address neurologic and psychiatric manifestations separately.

Neurologic symptoms may improve with treatment if identified early, but delayed diagnosis can limit reversibility. Psychiatric symptoms, in particular, are often persistent and require dedicated management, including pharmacologic and supportive care.

Long-term adherence to therapy remains a significant challenge, especially among patients diagnosed at a younger age. Panelists highlighted the importance of multidisciplinary care teams, including pharmacists, dietitians, and mental health professionals, to support adherence and optimize outcomes.

Family screening was also emphasized, given the genetic nature of the disease, with siblings and relatives often requiring evaluation.

Emerging Therapies and Future Directions

Looking ahead, participants discussed the potential impact of emerging therapies, including gene therapy and novel agents targeting copper metabolism. Early data from clinical trials suggest that gene therapy may allow some patients to discontinue standard treatments, though these approaches remain investigational.

New diagnostic tools are also under investigation, including biomarkers and advanced histologic techniques that may improve diagnostic accuracy in challenging cases.

Despite these advances, experts emphasized that improving outcomes in Wilson disease will depend largely on earlier recognition and more consistent application of existing diagnostic strategies.

The Continued Need for Awareness

The discussion underscored a key challenge in Wilson disease care: while effective treatments exist, they are only impactful when the disease is identified early. Given the variability in presentation and limitations of current diagnostic tools, clinicians must remain vigilant, particularly when evaluating younger patients with unexplained hepatic, neurologic, or psychiatric symptoms.

As research continues to advance, the potential to improve outcomes is growing. However, for now, panelists agreed that heightened awareness and clinical suspicion remain the most powerful tools for closing the diagnostic gap in Wilson disease.

References

1. Wilson Disease Association. Wilson Disease. Published August 13, 2021. Accessed April 15, 2026. https://wilsondisease.org/do-i-have-wilson-disease/?gad_source=1&gad_campaignid=16684019432&gbraid=0AAAAADN9hfNH0Qklo1N7KKX3qO0womQLJ&gclid=CjwKCAiAw9vIBhBBEiwAraSATuJdNxoP57_7zjL0DUUF0B9EceR3whBrdSIFmutmQSsj2E3BL4nQkhoC-xwQAvD_BwE

2. NIDDK. Diagnosis of Wilson Disease. October 2018. Accessed April 15, 2026. https://www.niddk.nih.gov/health-information/liver-disease/wilson-disease/diagnosis